BRPI0409124A - miméticos de direção inversa e método relacionado aos mesmos - Google Patents

miméticos de direção inversa e método relacionado aos mesmos

Info

Publication number
BRPI0409124A
BRPI0409124A BRPI0409124-8A BRPI0409124A BRPI0409124A BR PI0409124 A BRPI0409124 A BR PI0409124A BR PI0409124 A BRPI0409124 A BR PI0409124A BR PI0409124 A BRPI0409124 A BR PI0409124A
Authority
BR
Brazil
Prior art keywords
reverse direction
disease
mimetics
biologically active
disclosed
Prior art date
Application number
BRPI0409124-8A
Other languages
English (en)
Inventor
Sung-Hwan Moon
Jae-Uk Chung
Sung-Chan Lee
Masakatsu Eguchi
Michael Kahn
Kwang-Won Jeong
Cu Nguyen
Original Assignee
Choongwae Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharma Corp filed Critical Choongwae Pharma Corp
Publication of BRPI0409124A publication Critical patent/BRPI0409124A/pt
Publication of BRPI0409124B1 publication Critical patent/BRPI0409124B1/pt
Publication of BRPI0409124B8 publication Critical patent/BRPI0409124B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MIMéTICOS DE DIREçãO INVERSA E MéTODO RELACIONADO AOS MESMOS". São divulgados compostos comprimidos de maneira conformacional que copiam a estrutura secundária de regiões de direção inversa de peptídeos e proteínas biologicamente ativos. Tais estruturas miméticas de direção inversa têm utilidade sobre uma ampla faixa de campos, incluindo o uso como agentes diagnósticos e terapêuticos. São também divulgadas bibliotecas contendo as estruturas miméticas de direção inversa desta invenção, assim como métodos para a triagem das mesmas para identificar membros biologicamente ativos. A invenção também se relaciona ao uso de tais compostos para inibir ou tratar distúrbios modulados pela via de sinalização de Wnt, tais como o câncer, especialmente o câncer colorretal, a reestenose associada com a angioplastia, a doença do rim policístico, a doença da angiogênese anormal, a doença de artrite reumatóide, o complexo de esclerose tuberosa, a doença de Alzheimer, o crescimento ou a perda em excesso de cabelo, ou a colite ulcerativa.
BRPI0409124A 2003-04-09 2004-03-17 miméticos de direção inversa, biblioteca, uso destes e método relacionado aos mesmos BRPI0409124B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/411,877 2003-04-09
US10/411,877 US20040072831A1 (en) 2001-10-12 2003-04-09 Reverse-turn mimetics and method relating thereto
PCT/US2004/008270 WO2004093828A2 (en) 2003-04-09 2004-03-17 Reverse-turn mimetics and method relating thereto

Publications (3)

Publication Number Publication Date
BRPI0409124A true BRPI0409124A (pt) 2006-05-02
BRPI0409124B1 BRPI0409124B1 (pt) 2020-11-03
BRPI0409124B8 BRPI0409124B8 (pt) 2021-05-25

Family

ID=33309485

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409124A BRPI0409124B8 (pt) 2003-04-09 2004-03-17 miméticos de direção inversa, biblioteca, uso destes e método relacionado aos mesmos

Country Status (11)

Country Link
US (1) US20040072831A1 (pt)
EP (1) EP1611130A4 (pt)
JP (1) JP4657201B2 (pt)
KR (1) KR101071978B1 (pt)
CN (1) CN1798746B (pt)
AU (1) AU2004231514B2 (pt)
BR (1) BRPI0409124B8 (pt)
CA (1) CA2521846C (pt)
NZ (1) NZ543186A (pt)
RU (1) RU2342387C2 (pt)
WO (1) WO2004093828A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7531320B2 (en) * 2003-08-28 2009-05-12 Choongwae Pharma Corporation Modulation of β-catenin/TCF-activated transcription
AU2005319166A1 (en) * 2004-12-22 2006-06-29 The Gillette Company Reduction of hair growth with survivin inhibitors
CA2612475C (en) * 2005-06-20 2015-07-28 Decode Genetics Ehf. Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
TW200800213A (en) * 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
ES2570994T3 (es) * 2005-11-08 2016-05-23 Choongwae Pharma Corp Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer
US20080249305A1 (en) * 2007-03-27 2008-10-09 Calderwood David J Novel imidazole based heterocycles
DK2303887T3 (en) * 2008-06-06 2015-11-02 Prism Pharma Co Ltd Alpha helix mimetics, and APPROACHES Relating THEREOF
CN101408911B (zh) * 2008-07-15 2010-06-09 北京科技大学 一类蛋白质二级结构智能预测模型构造技术
JP5545573B2 (ja) * 2008-10-14 2014-07-09 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ アルファへリックスミメティック及び関連の方法
MX340424B (es) * 2009-04-15 2016-07-08 Jw Pharmaceutical Corp Compuestos novedosos de mimeticos de cambio inverso; metodo para fabricarlos y su uso.
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
EP2533048A4 (en) 2010-02-03 2013-08-21 Prism Biolab Co Ltd CONNECTION TO THE BINDING OF NATURALLY OBTAINING DENATURED PROTEINS AND METHOD FOR SCREENING AFTER THIS CONNECTION
KR102168006B1 (ko) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
US8940739B2 (en) 2010-10-14 2015-01-27 Jw Pharmaceutical Corporation Compound of a reverse-turn mimetic and a production method and use therefor
KR102077871B1 (ko) 2010-11-16 2020-02-14 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
CN103221094B (zh) * 2010-11-19 2016-04-20 诺华有限公司 Mdm2/4及p53相互作用抑制剂的结晶型
US9353119B2 (en) 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
PT2754441E (pt) * 2011-08-09 2016-06-24 Jw Pharmaceutical Corp Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina
AU2012319069A1 (en) * 2011-10-07 2014-05-29 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
PL2841075T3 (pl) 2012-04-26 2020-09-21 The General Hospital Corporation Środki i sposoby leczenia i zapobiegania rogowaceniu łojotokowemu
EP2888265B1 (en) * 2012-08-23 2017-10-11 The Regents of The University of Michigan Bivalent inhibitors of iap proteins and therapeutic methods using the same
JP6303112B2 (ja) 2012-12-12 2018-04-04 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤
US10508309B2 (en) 2013-05-17 2019-12-17 The General Hospital Corporation Methods for detecting and treating variants of seborrheic keratoses
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
WO2017047762A1 (ja) * 2015-09-18 2017-03-23 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
TW202137984A (zh) 2019-10-29 2021-10-16 日商衛材R&D企管股份有限公司 用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
KR20210153908A (ko) * 2020-06-11 2021-12-20 제이더블유중외제약 주식회사 코로나바이러스감염증-19(covid-19) 치료용 조성물
WO2023027888A1 (en) * 2021-08-26 2023-03-02 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6410245B1 (en) * 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2003031448A1 (en) * 2001-10-12 2003-04-17 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ATE393769T1 (de) * 2003-02-13 2008-05-15 Sanofi Aventis Deutschland Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2515735A1 (en) * 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments

Also Published As

Publication number Publication date
JP2006523680A (ja) 2006-10-19
EP1611130A2 (en) 2006-01-04
AU2004231514B2 (en) 2009-12-10
KR101071978B1 (ko) 2011-10-10
EP1611130A4 (en) 2010-06-16
JP4657201B2 (ja) 2011-03-23
CA2521846A1 (en) 2004-11-04
BRPI0409124B8 (pt) 2021-05-25
CA2521846C (en) 2009-10-13
AU2004231514A1 (en) 2004-11-04
WO2004093828A2 (en) 2004-11-04
CN1798746B (zh) 2010-09-08
CN1798746A (zh) 2006-07-05
RU2342387C2 (ru) 2008-12-27
KR20050115333A (ko) 2005-12-07
BRPI0409124B1 (pt) 2020-11-03
NZ543186A (en) 2008-04-30
US20040072831A1 (en) 2004-04-15
WO2004093828A3 (en) 2005-07-28
RU2005134660A (ru) 2006-05-27

Similar Documents

Publication Publication Date Title
BRPI0409124A (pt) miméticos de direção inversa e método relacionado aos mesmos
BRPI0509888A (pt) miméticos de direção inversa e método relacionado aos mesmos
ATE203025T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
ATE398129T1 (de) Reverse-turn-mimetika und diese betreffendes verfahren
CA2286733A1 (en) Reverse-turn mimetics and methods relating thereto
ATE301656T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
WO1992013878A3 (en) Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
DE60043120D1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
PT934325E (pt) Trisanidridos biciclicos de tetrafosfonato
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
BR9915604A (pt) Peptìdios inibidores de tgfbeta1
DE69327645T2 (de) Dna-sequenzen kodierend für neuartige wachstums-/differentierungsfaktoren
BRPI9915679B8 (pt) composições e métodos para aumentar a mineralização óssea
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
WO1998010076A3 (en) Phospholipase d and dna sequences
BR0318325A (pt) miméticos de beta-fita e método relacionado aos mesmos
DE69922429D1 (de) Verwendung eines Adsorptionsmittels für die Trennung von halogenierten aromatischen Verbindungen und Trennungsverfahren unter Verwendung dieses Adsorptionsmittels
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
BR112023024627A2 (pt) Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
DE60236871D1 (de) Verwendung von peptidfragmenten aus der alpha-1 untereinheit von kalziumkanälen, die mutationen enthalten können, für das screening von molekülen mit therapeutischem potential
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
ATE329046T1 (de) Parvovirus-vektoren und deren verwendung
ITMI930677A0 (it) Procedimento per la depurazione di acque inquinate da solfuri e/o sostanze organiche varie, particolarmente provenienti da concerie, dietetici e simili e relativa apparecchiatura

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2714 DE 10-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.